FDA Seeks Input on Keeping Tobacco Ads from Teens
Published Date: 2/18/2026
Notice
Summary
The FDA is asking for feedback on rules that keep cigarettes and smokeless tobacco away from kids and teens. Tobacco makers, sellers, and advertisers must tell the FDA if they plan to use new types of ads or labels not already approved. Comments are open until March 20, 2026, and this helps make sure tobacco stays out of young hands without adding extra costs.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Tobacco Firms Must Notify FDA
If you are a tobacco product manufacturer, distributor, or retailer and plan to use an advertising or labeling medium not listed in 21 CFR 1140.30(a)(1), you must notify FDA describing the medium and how much it may be seen by persons younger than 18. The notice must be submitted 30 days before using the medium.
Short, Flexible Submission Process
FDA allows electronic or mail submission of the notices and provides guidance on formatting; FDA estimates each notice takes about 1 hour and expects about 4 notices per year. FDA states there are no capital or operating costs associated with this collection.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-03097, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Electronic Products Requirements
The FDA is updating its paperwork rules for electronic products that emit radiation to keep everyone safe. If you make or sell these products, you might need to provide some info to the government. Comments on these changes are open until March 20, 2026, so now’s the time to speak up!
Next: 2026-03099, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request Data To Support Social and Behavioral Research as Used by the Food and Drug Administration
The FDA is asking for approval to keep collecting information that helps them understand how people think and behave about health topics. This info guides their decisions and communications, affecting patients, healthcare pros, and consumers. Comments on this plan are open until March 20, 2026, with no new costs expected.